Cargando…
Type 1 Diabetes: Disease Stratification
Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratificat...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945911/ https://www.ncbi.nlm.nih.gov/pubmed/31988942 http://dx.doi.org/10.1159/000481131 |
_version_ | 1783485258489921536 |
---|---|
author | Insel, Richard Dutta, Sanjoy Hedrick, Joseph |
author_facet | Insel, Richard Dutta, Sanjoy Hedrick, Joseph |
author_sort | Insel, Richard |
collection | PubMed |
description | Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease. |
format | Online Article Text |
id | pubmed-6945911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-69459112020-01-27 Type 1 Diabetes: Disease Stratification Insel, Richard Dutta, Sanjoy Hedrick, Joseph Biomed Hub Article Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease. S. Karger AG 2017-11-21 /pmc/articles/PMC6945911/ /pubmed/31988942 http://dx.doi.org/10.1159/000481131 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Article Insel, Richard Dutta, Sanjoy Hedrick, Joseph Type 1 Diabetes: Disease Stratification |
title | Type 1 Diabetes: Disease Stratification |
title_full | Type 1 Diabetes: Disease Stratification |
title_fullStr | Type 1 Diabetes: Disease Stratification |
title_full_unstemmed | Type 1 Diabetes: Disease Stratification |
title_short | Type 1 Diabetes: Disease Stratification |
title_sort | type 1 diabetes: disease stratification |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945911/ https://www.ncbi.nlm.nih.gov/pubmed/31988942 http://dx.doi.org/10.1159/000481131 |
work_keys_str_mv | AT inselrichard type1diabetesdiseasestratification AT duttasanjoy type1diabetesdiseasestratification AT hedrickjoseph type1diabetesdiseasestratification |